US patent granted for cancer treatment compound

Regulatory product approvalBusiness Updates View source PDF Explain this filing

GODAVARIB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹228.90

prior close

₹243.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+4.4% vs market

Fast Moving Consumer Goods peers, median of 296sector · sector level-0.7%+3.4% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 3.4 pts more than its Fast Moving Consumer Goods peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.4

10m

+6.2

15m

+7.0

30m

+5.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7-1.6+4.4-0.7+3.4

Next day

+3.5-1.0+4.5-0.7+4.2

+1.8-2.6+4.4-1.8+3.5

-3.2-5.1+2.0-3.8+0.6

-2.6-6.1+3.5-5.4+2.9

-11.3-8.3-3.0-7.1-4.2

-10.6-6.4-4.2-6.1-4.4

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Fast Moving Consumer Goods peers, median of 296Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Godavari Biorefineries has been granted a US patent for '5-Hydroxy-1,4-Naphthalenedione,' a novel compound for cancer treatment. The patent protects compounds that effectively inhibit cancer and cancer stem cells, showing significant potential against breast and prostate cancers. The company has shared the grant certificate with the exchanges.

Likely market impact

Positive for the company's R&D pipeline and IP portfolio, though no immediate revenue impact. Strengthens long-term oncology prospects.